Active ingredientDantroleneCat. No. P-D012-001CAS 7261-97-4Family · Pharmaceutical analytical standards
Dantrolene
A muscle relaxant that acts directly on muscle, curbing calcium release through the ryanodine receptor; first described in 1967, it is the main medicine for malignant hyperthermia, a rare reaction to anaesthesia, and is also used for spasticity. This family brings together the active ingredient, pharmacopoeial impurities, metabolites, labelled standards and other impurities.
Did you know?Its effect against malignant hyperthermia was shown in the 1970s by South African anaesthetist Gaisford Harrison, in pigs that naturally carry the same genetic predisposition.
Go to the active ingredient →Active ingredientDantroleneCat. No. P-D012-001CAS 7261-97-4
Active ingredientDantrolene Sodium HydrateCat. No. P-D012-002CAS 24868-20-0
Active ingredientDantrolene Sodium SaltCat. No. P-D012-003CAS 14663-23-1
Pharmacopoeial impurityDantrolene USP Related Compound ACat. No. P-D012-004CAS 301359-05-7
Pharmacopoeial impurityDantrolene USP Related Compound CCat. No. P-D012-005CAS 7147-77-5
Metabolite5-Hydroxy Dantrolene GlucuronideCat. No. P-D012-006
Isotopically labelled5-Hydroxy Dantrolene-d4Cat. No. P-D012-007CAS 1217225-15-4
Isotopically labelledDantrolene-d4Cat. No. P-D012-008CAS 2749234-17-9
Impurity(E)-Dantrolene Sodium SaltCat. No. P-D012-009CAS 1231955-65-9
Impurity5-Hydroxy DantroleneCat. No. P-D012-010CAS 52130-25-3
Impurity5-Hydroxy Dantrolene SulfateCat. No. P-D012-011
ImpurityAminodantroleneCat. No. P-D012-012CAS 14663-28-6
ImpurityDantrolene Impurity 1Cat. No. P-D012-013
ImpurityDantrolene Impurity 2Cat. No. P-D012-014CAS 55227-60-6
ImpurityDantrolene Impurity 3Cat. No. P-D012-015
ImpurityDantrolene Impurity 4Cat. No. P-D012-016CAS 57268-33-4No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.